Skip to main content
ASH 2017: ASH 2017: Prevention of dysbiosis complications with autologous fecal microbiota transplantation (auto-FMT) in AML patients undergoing intensive treatment (ODYSSEE study): First results of a prospective multicenter trial
Posters

ASH 2017: ASH 2017: Prevention of dysbiosis complications with autologous fecal microbiota transplantation (auto-FMT) in AML patients undergoing intensive treatment (ODYSSEE study): First results of a prospective multicenter trial

By December 10, 2017March 10th, 2022No Comments
MaaT Pharma dans les médias MaaT Pharma in the News